Sort   by:  
 Page size 
UnknownFeasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Not available
S-EPMC5657012 | biostudies-literature
UnknownPhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Not available
S-EPMC4021043 | biostudies-literature
UnknownCorrelative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Not available
S-EPMC5070556 | biostudies-literature
TranscriptomicsA predictive and prognostic 38-gene expression signature for metastatic relapse in breast cancer
Background Currently, no gene-expression signature (GES) established from node-positive cohorts, able to predict breast cancer evolution after systemic adjuvant chemotherapy, exists. Methods Gene-expression profiles of 252 node-positive patients (median follow-up: 7.7 years), mostly included in a ra...
ORGANISM(S): Homo sapiens 
2008-11-27 | E-GEOD-11264 | biostudies-arrayexpress
TranscriptomicsGene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Triple-negative (TN) breast cancers need to be refined in order to identify therapeutic subgroups of patients. We conducted an unsupervised analysis of microarray gene-expression profiles of 107 TN breast cancer patients and undertook robust functional annotation of the molecular entities found by ...
ORGANISM(S): Homo sapiens 
2015-05-19 | E-GEOD-58812 | biostudies-arrayexpress
UnknownEvaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Not available
S-EPMC6865065 | biostudies-literature
GenomicsWhole-exome sequencing of breast cancer metastasis and corresponding blood samples
This study included samples from metastatic breast cancer patients who underwent a biopsy in the context of SAFIR01 (NCT01414933), SAFIR02 (NCT02299999), SHIVA (NCT01771458) and MOSCATO (NCT01566019) prospective trials. These French multicentre trials used high throughput genome analysis on fresh fr...
EGAS00001001695 | EGA
Genomicsena-DATASET-IGR-28-10-2016-14:22:46:181-287 - samples
Whole-exome sequencing (WES) of 216 breast cancer metastasis-normal pairs from patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA or MOSCATO prospective trials (France).
EGAD00001002747 | EGA
GenomicsData Access Committee for the Metastatic Breast Cancer Whole-exome sequencing study
Data Access Committee EGAC00001000434
EGAC00001000434 | EGA
UnknownTumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.
Not available
S-EPMC8029323 | biostudies-literature
Sort   by:  
 Page size